Arcutis Biotherapeutics Inc.

09/28/2021 | Press release | Distributed by Public on 09/28/2021 04:03

Material Definitive Agreement (Form 8-K)

Entry into a Material Definitive Agreement

On September 22, 2021, Arcutis Biotherapeutics, Inc. ("Arcutis" or the "Company") entered into a Supply and Manufacturing Agreement (the "Supply Agreement") with DPT Laboratories, Ltd. ("DPT") for the manufacture and commercial supply of topical Roflumilast Cream (ARQ-151), its lead product candidate (the "Product"). Pursuant to the terms of the Supply Agreement, DPT has agreed to manufacture and supply the Product in accordance with specifications and quality standards established by the parties and the Company has agreed to purchase from DPT a minimum portion of its supply of the Product for the term of the Supply Agreement. The initial term of the Supply Agreement commenced on September 15, 2021 and lasts until December 31, 2025, and will automatically renew for successive twenty-four (24) month terms unless earlier terminated. The Supply Agreement may be terminated by either party upon sixty (60) days written notice of an uncured material breach.

The Supply Agreement contains, among other provisions, representation and warranties, indemnification obligations, confidentiality, audit and inspection, and intellectual property sharing provisions in favor of each party that are customary for an agreement of this nature.

The foregoing summary of the material terms of the Supply Agreement is qualified in its entirety by the terms of the Supply Agreement, which will be filed as an exhibit to the Company's Quarterly Report for the nine months ending September 30, 2021.

Financial Statements and Exhibits
(d) Exhibits.
Exhibit No.
104 Cover Page Interactive Data File, formatted in inline XBRL.